Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Sep 30;12(4):2057–2073. doi: 10.1016/j.apsb.2021.09.022

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

In vivo anti-tumor treatment of LF-Lipo + αPD-1 in CT26 subcutaneous tumor in situ recurrence model. (A) Therapeutic schedule. (B) Tumor growth curve. (C) Tumor weight of the primary tumor. (D) Tumor tissues. (E‒I) Individual tumor growth curves of control, αPD-1, Pano + JQ1, LF-Lipo, and LF-Lipo + αPD-1 groups. (J) Tumor weight of the recurrent tumor after surgical removal of the primary tumors. Data are presented as mean ± SD (n = 6). ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001. ns, not significant.